^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Non Small Cell Lung Cancer

    Related cancers:
    Apply
    Single Fraction Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Non-small Cell Lung Cancer (NCI-2019-04325) (NCT04073745)
    Phase 1
    Roswell Park Cancer Institute
    Recruiting
    Last update posted :
    02/28/2025
    Initiation :
    12/04/2019
    Primary completion :
    06/01/2025
    Completion :
    11/01/2025
    IL2RA • CD4 • FOXP3 • ISG20
    Study of Longitudinal Plasma PD-L1 Testing With Immunotherapy in Lung Cancer (NCT06849518)
    Phase N/A
    Ballad Health
    Recruiting
    Last update posted :
    02/28/2025
    Initiation :
    02/11/2025
    Primary completion :
    03/01/2026
    Completion :
    03/01/2027
    PD-L1
    |
    PD-L1 expression
    Improving Genomic Profiling and Reducing Time to Cancer Treatment Via Targeted Use of Endoscopic Ultrasound (IMPROVED) (NCT06848738)
    Phase N/A
    Zealand University Hospital
    Enrolling by invitation
    Last update posted :
    02/27/2025
    Initiation :
    05/07/2024
    Primary completion :
    06/01/2026
    Completion :
    06/01/2026
    BRAF
    Clinical Application of PET Imaging Targeting MSLN in Malignant Tumors (NCT06843629)
    Phase N/A
    Wuhan Union Hospital, China
    Recruiting
    Last update posted :
    02/25/2025
    Initiation :
    10/01/2024
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    MSLN
    Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer (NCT04181060)
    Phase 3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    12/28/2020
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation
    |
    Avastin (bevacizumab) • Tagrisso (osimertinib) • Aybintio (bevacizumab biosimilar) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Krabeva (bevacizumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)
    Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial (ACCIO) (NCT04267848)
    Phase 3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    06/16/2020
    Primary completion :
    12/15/2025
    Completion :
    12/15/2025
    EGFR • PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • pemetrexed • Pembroria (pembrolizumab biosimilar) • liposomal gemcitabine (FF-10832)
    Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial (ACHIEVE Study) (NCT06096844)
    Phase 3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    07/19/2024
    Primary completion :
    06/01/2026
    Completion :
    06/01/2026
    EGFR • PD-L1 • ALK
    |
    ALK translocation • EGFR negative
    |
    Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)
    Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) (NCT02194738)
    Phase N/A
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    09/26/2014
    Primary completion :
    09/28/2026
    Completion :
    09/28/2026
    EGFR • PD-L1 • ALK • PIK3CA • PTEN • PD-1 • CTLA4
    |
    EGFR mutation • ALK rearrangement
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Lynparza (olaparib) • cisplatin • Xalkori (crizotinib) • erlotinib • carboplatin • gemcitabine • paclitaxel • docetaxel • Mektovi (binimetinib) • pemetrexed • sapanisertib (CB-228) • Zaltrap (ziv-aflibercept IV) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • Pembroria (pembrolizumab biosimilar) • Pemfexy (pemetrexed) • liposomal gemcitabine (FF-10832)
    Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change (NCT03191149)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    04/25/2018
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    EGFR • PD-1 • CTLA4
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Tagrisso (osimertinib)
    Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors (NCT04119024)
    Phase 1
    Jonsson Comprehensive Cancer Center
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    11/27/2019
    Primary completion :
    10/01/2025
    Completion :
    10/01/2026
    BRAF
    |
    BRAF mutation • BRAF V600
    |
    cyclophosphamide • fludarabine IV • Imunace (teceleukin) • MB-101 • cyclophosphamide intravenous
    DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer (KEYNOTE-797) (NCT04042701)
    Phase 1
    Daiichi Sankyo
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    02/10/2020
    Primary completion :
    07/01/2025
    Completion :
    08/01/2025
    EGFR • HER-2 • BRAF • ALK • ROS1
    |
    HER-2 positive • BRAF V600E • EGFR mutation • HR positive • BRAF V600 • HER-2 expression • HER-2 underexpression • ALK mutation • ROS1 fusion
    |
    Keytruda (pembrolizumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)
    Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) (NCT05853575)
    Phase 2
    Mirati Therapeutics Inc.
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    02/16/2024
    Primary completion :
    03/31/2025
    Completion :
    03/31/2025
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Krazati (adagrasib)
    Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib (Acclaim-1) (NCT04486833)
    Phase 1/2
    Genprex, Inc.
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    09/03/2021
    Primary completion :
    03/01/2028
    Completion :
    03/01/2029
    EGFR
    |
    EGFR mutation
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • Reqorsa (quaratusugene ozeplasmid)
    ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003) (NCT05671510)
    Phase 3
    OncoC4, Inc.
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    06/28/2023
    Primary completion :
    06/30/2026
    Completion :
    06/30/2027
    LAG3 • CTLA4 • TIGIT
    |
    docetaxel • gotistobart (BNT316)
    Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 (NCT04613596)
    Phase 2/3
    Mirati Therapeutics Inc.
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    12/02/2020
    Primary completion :
    10/31/2028
    Completion :
    10/31/2029
    PD-L1 • KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • Krazati (adagrasib)
    Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer (NCT05642195)
    Phase 1/2
    National Cancer Institute (NCI)
    Suspended
    Last update posted :
    02/24/2025
    Initiation :
    02/27/2025
    Primary completion :
    12/30/2033
    Completion :
    12/30/2035
    PD-L1
    |
    PD-L1 expression
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • H1299 lung cancer cell lysate vaccine with Montanide ISA-51 VG adjuvant
    A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004) (NCT06345729)
    Phase 3
    Merck Sharp & Dohme LLC
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    05/24/2024
    Primary completion :
    02/19/2029
    Completion :
    02/18/2031
    KRAS
    |
    Keytruda (pembrolizumab) • MK-1084
    Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer (NRG-LU003) (NCT03737994)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    07/25/2019
    Primary completion :
    07/21/2021
    Completion :
    12/02/2025
    MET
    |
    ALK positive • MET amplification • ALK rearrangement
    |
    cisplatin • Xalkori (crizotinib) • carboplatin • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • pemetrexed • Alunbrig (brigatinib) • Ensacove (ensartinib) • Pemfexy (pemetrexed)
    A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer (NAUTIKA1) (NCT04302025)
    Phase 2
    Genentech, Inc.
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    11/06/2020
    Primary completion :
    12/30/2025
    Completion :
    03/06/2029
    PD-L1 • KRAS • BRAF • ALK • RET • ROS1 • NTRK1 • NTRK3 • NTRK2
    |
    PD-L1 expression • KRAS mutation • KRAS G12C • BRAF mutation • BRAF V600 • RET fusion • ALK fusion • RET mutation • ROS1 fusion • KRAS G12
    |
    Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Rozlytrek (entrectinib) • Alecensa (alectinib) • Cotellic (cobimetinib) • Gavreto (pralsetinib) • divarasib (RG6330)
    Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors (NCT05887492)
    Phase 1/2
    Tango Therapeutics, Inc.
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    06/12/2023
    Primary completion :
    01/01/2026
    Completion :
    06/01/2026
    STK11
    |
    STK11 mutation
    |
    Keytruda (pembrolizumab) • TNG260
    Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations (NCT06043713)
    Phase 1
    Fred Hutchinson Cancer Center
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    12/15/2023
    Primary completion :
    12/31/2025
    Completion :
    02/09/2026
    HER-2 • KRAS • BRAF • ALK • TMB • MSI • NTRK
    |
    KRAS mutation • TMB-H • BRAF mutation • HER-2 amplification • ROS1 fusion • KRAS G12 • NTRK fusion
    |
    cyclophosphamide • bendamustine • fludarabine IV
    Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006) (NCT03829319)
    Phase 3
    Merck Sharp & Dohme LLC
    Completed
    Last update posted :
    02/21/2025
    Initiation :
    03/25/2019
    Primary completion :
    08/11/2023
    Completion :
    08/30/2024
    EGFR • ALK • ROS1
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • Lenvima (lenvatinib) • pemetrexed
    Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy (ENDURE) (NCT04892953)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    07/07/2021
    Primary completion :
    09/30/2026
    Completion :
    09/30/2026
    EGFR • ALK • MET • RET • ROS1
    |
    RET fusion • ALK rearrangement • MET exon 14 mutation • ALK fusion • ROS1 fusion • ROS1 rearrangement • RET rearrangement
    |
    carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)
    Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer (KontRASt-02) (NCT05132075)
    Phase 3
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    06/23/2022
    Primary completion :
    10/01/2025
    Completion :
    10/31/2025
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    docetaxel • opnurasib (JDQ443)
    A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway (NCT05578092)
    Phase 1/2
    Mirati Therapeutics Inc.
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    12/02/2022
    Primary completion :
    06/30/2026
    Completion :
    07/30/2026
    EGFR • KRAS • NF1 • PTPN11
    |
    KRAS mutation • EGFR mutation • KRAS G12C • KRAS G12
    |
    Krazati (adagrasib) • MRTX0902
    A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC (ARTEMIDE-Lung03) (NCT06627647)
    Phase 3
    AstraZeneca
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    11/27/2024
    Primary completion :
    05/10/2029
    Completion :
    03/25/2030
    PD-L1
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • rilvegostomig (AZD2936)
    Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer (AIM-NIVO) (NCT03816345)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    07/16/2019
    Primary completion :
    08/31/2026
    Completion :
    08/31/2026
    MSI • IL2
    |
    Opdivo (nivolumab) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)
    A Study of SGN-PDL1V in Advanced Solid Tumors (SGNPDL1V-001) (NCT05208762)
    Phase 1
    Seagen Inc.
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    10/25/2022
    Primary completion :
    11/18/2027
    Completion :
    11/17/2028
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • PF-08046054
    A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (LIBRETTO-432) (NCT04819100)
    Phase 3
    Eli Lilly and Company
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    12/20/2021
    Primary completion :
    05/01/2027
    Completion :
    08/01/2032
    RET
    |
    RET fusion
    |
    Retevmo (selpercatinib)
    Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2) (KRYSTAL-2) (NCT04330664)
    Phase 1
    Mirati Therapeutics Inc.
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    04/07/2020
    Primary completion :
    07/29/2022
    Completion :
    02/24/2025
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Krazati (adagrasib) • batoprotafib (TNO155)
    Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease (NCT03808337)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    01/16/2019
    Primary completion :
    01/01/2026
    Completion :
    01/01/2026
    EGFR • HER-2 • ALK • ROS1
    Endoxifen in Adults With Hormone Receptor Positive Solid Tumors (NCT01273168)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    03/01/2011
    Primary completion :
    06/01/2020
    Completion :
    06/01/2026
    HER-2
    |
    tamoxifen • Zonalta (Z-endoxifen hydrochloride)
    Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab (M21-404) (NCT05029882)
    Phase 1
    AbbVie
    Active, not recruiting
    Last update posted :
    02/20/2025
    Initiation :
    10/13/2021
    Primary completion :
    11/01/2025
    Completion :
    11/01/2025
    MET
    |
    MET amplification • EGFR wild-type
    |
    Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil) • telisotuzumab adizutecan (ABBV-400)
    A Study of SGN-B6A in Advanced Solid Tumors (SGNB6A-001) (NCT04389632)
    Phase 1
    Seagen Inc.
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    06/08/2020
    Primary completion :
    11/30/2026
    Completion :
    02/28/2028
    HER-2
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • sigvotatug vedotin (PF-08046047)
    A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) (NCT03940703)
    Phase 2
    EMD Serono Research & Development Institute, Inc.
    Active, not recruiting
    Last update posted :
    02/20/2025
    Initiation :
    09/19/2019
    Primary completion :
    05/11/2023
    Completion :
    10/31/2025
    EGFR • MET
    |
    EGFR mutation • MET amplification
    |
    Tagrisso (osimertinib) • Tepmetko (tepotinib)
    A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer (Be6A Lung-01). (NCT06012435)
    Phase 3
    Seagen Inc.
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    02/21/2024
    Primary completion :
    07/31/2026
    Completion :
    07/31/2028
    PD-L1
    |
    docetaxel • sigvotatug vedotin (PF-08046047)
    A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation (ALAFOSS-01) (NCT06599502)
    Phase 1/2
    AstraZeneca
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    10/18/2024
    Primary completion :
    01/20/2028
    Completion :
    01/20/2028
    KRAS
    |
    KRAS mutation • KRAS G12D
    |
    Erbitux (cetuximab)
    A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20) (CheckMate 8KX) (NCT03656718)
    Phase 1/2
    Bristol-Myers Squibb
    Completed
    Last update posted :
    02/20/2025
    Initiation :
    10/29/2018
    Primary completion :
    09/07/2022
    Completion :
    09/12/2024
    MSI
    |
    MSI-H/dMMR
    |
    Opdivo (nivolumab) • Opdivo Qvantig (nivolumab and hyaluronidase-nvhy)
    A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors (NCT05487235)
    Phase 1
    Genentech, Inc.
    Active, not recruiting
    Last update posted :
    02/20/2025
    Initiation :
    08/17/2022
    Primary completion :
    03/31/2026
    Completion :
    03/31/2026
    EGFR • BRAF • ALK
    |
    PD-L1 expression • BRAF wild-type
    |
    Tecentriq (atezolizumab) • migoprotafib (RLY-1971) • omeprazole
    Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer (NCT03937154)
    Phase 3
    Amgen
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    02/26/2020
    Primary completion :
    05/20/2026
    Completion :
    05/20/2027
    HER-2
    |
    Nplate (romiplostim)
    A Study of SGN-EGFRd2 in Advanced Solid Tumors (SGNEGFRd2-001) (NCT05983133)
    Phase 1
    Seagen Inc.
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    11/14/2023
    Primary completion :
    07/31/2027
    Completion :
    09/30/2028
    EGFR • ALK • MSI
    |
    EGFR mutation • MSI-H/dMMR • ALK rearrangement
    |
    PF-08046052
    Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists (CHECK'UP) (NCT03412058)
    Phase N/A
    UNICANCER
    Active, not recruiting
    Last update posted :
    02/20/2025
    Initiation :
    06/27/2018
    Primary completion :
    01/02/2024
    Completion :
    12/01/2025
    EGFR • ALK
    |
    PD-L1 expression • PD-L1 overexpression • ALK negative